|
**Overview**: Prenatal Comprehensive Screening 1 Panel**Introduction**: The Prenatal Comprehensive Screening 1 Panel is a diagnostic tool designed for comprehensive prenatal screening using serum samples. In India, combined first- and second-trimester screening detects ~90 percent of Down syndrome (trisomy 21) and ~80 percent of open neural tube defects, with prevalence of chromosomal anomalies ~1 in 800-1000 births and NTDs ~1-2 per 1000 (higher in northern states due to folate deficiency). High morbidity from under-screening in rural/low-SES pregnancies, limited labs, delayed anomaly detection leading to late termination or birth of affected child. Per obstetrics practices aligned with ICMR, FOGSI, and Indian Society of Perinatology guidelines, the test employs immunoassay for free beta-hCG, PAPP-A, AFP, estriol, inhibin A, NT measurement, and risk assessment over 1-2 days with high accuracy, valuable for integrated risk calculation (FMF algorithm). This diagnostic falls under prenatal screening and targets pregnant women in first/second trimester, addressing accurate detection to guide CVS/amniocentesis or continuation counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early risk stratification and reducing birth defects burden. Its serum-based approach ensures reliable multi-marker profiling.**Other Names**: Prenatal Comp Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Integrated screening standard since 2000s; in India, scaled under maternal health programs.**Purpose**: The test assesses 7 parameters including free beta-hCG to guide fetal abnormality screening, calculate integrated risk, inform invasive testing.**Test Parameters**: 1. Free Beta-hCG, 2. PAPP-A, 3. AFP, 4. Estriol, 5. Inhibin A, 6. NT, 7. Risk Assessment.**Pretest Condition**: Fasting 10-12 hours recommended; patients should be 11-20 weeks gestation with NT scan.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, NT, maternal age.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of false-positive/negative including anxiety or missed diagnosis, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and calculate risk using integrated algorithms within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or incorrect gestational age can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High risk (>1:250) indicates need for diagnostic testing, necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: NIPT, amniocentesis for confirmation.**Test Limitations**: Screening only (not diagnostic); comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Prenatal Studies India 2023. |
